AbbVie’s Rising Shares: Strong Earnings, Promising Trials, and R&D Surge Fuel Investor Optimism
AbbVie’s recent earnings reveal a 4.2 % revenue rise driven by Humira, while a 30 % boost in R&D signals a pipeline‑heavy future—investors watch clinical‑trial breakthroughs and competitive threats to gauge long‑term value.
4 minutes to read










